COHANCE — Cohance Lifesciences Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹396.53bn
- IN₹397.86bn
- IN₹11.98bn
Annual cashflow statement for Cohance Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
C2021 March 31st | 2022 March 31st | C2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 4,677 | 6,676 | 5,597 | 4,057 | 3,439 |
| Depreciation | |||||
| Non-Cash Items | 52.6 | 23.8 | -90 | -365 | -177 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1,216 | -3,782 | -1,400 | -625 | -1,156 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 3,825 | 3,300 | 4,572 | 3,585 | 2,882 |
| Capital Expenditures | -1,108 | -752 | -2,859 | -518 | -1,557 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -2,006 | -610 | 909 | -3,105 | -996 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3,114 | -1,362 | -1,950 | -3,623 | -2,553 |
| Financing Cash Flow Items | -86.7 | -61.4 | -116 | -74.5 | -104 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -757 | -1,564 | -2,420 | -138 | 33.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -45.1 | 374 | 202 | -176 | 382 |